spacer
spacer

PDBsum entry 1d0g

Go to PDB code: 
protein metals Protein-protein interface(s) links
Apoptosis PDB id
1d0g
Jmol PyMol
Contents
Protein chains
108 a.a. *
151 a.a. *
Metals
_ZN
_CL
Waters ×284
* Residue conservation analysis
PDB id:
1d0g
Name: Apoptosis
Title: Crystal structure of death receptor 5 (dr5) bound to apo2l/trail
Structure: Death receptor-5. Chain: r, s, t. Fragment: extracellular domain residues 1-130. Synonym: dr-5. Engineered: yes. Apoptosis-2 ligand. Chain: a, b, d. Fragment: residues 114-281. Synonym: trail, apo2l.
Source: Homo sapiens. Human. Organism_taxid: 9606. Expressed in: unidentified baculovirus. Expression_system_taxid: 10469. Promoter. Expressed in: bacteria. Expression_system_taxid: 2.
Biol. unit: Hexamer (from PQS)
Resolution:
2.40Å     R-factor:   0.222     R-free:   0.267
Authors: S.G.Hymowitz,H.W.Christinger,G.Fuh,M.P.O'Connell,R.F.Kelley, A.Ashkenazi,A.M.De Vos
Key ref:
S.G.Hymowitz et al. (1999). Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell, 4, 563-571. PubMed id: 10549288 DOI: 10.1016/S1097-2765(00)80207-5
Date:
09-Sep-99     Release date:   22-Oct-99    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
O14763  (TR10B_HUMAN) -  Tumor necrosis factor receptor superfamily member 10B
Seq:
Struc:
440 a.a.
108 a.a.
Protein chains
Pfam   ArchSchema ?
P50591  (TNF10_HUMAN) -  Tumor necrosis factor ligand superfamily member 10
Seq:
Struc:
281 a.a.
151 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Gene Ontology (GO) functional annotation 
  GO annot!
  Cellular component     membrane   1 term 
  Biological process     immune response   1 term 
  Biochemical function     TRAIL binding     2 terms  

 

 
DOI no: 10.1016/S1097-2765(00)80207-5 Mol Cell 4:563-571 (1999)
PubMed id: 10549288  
 
 
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.
S.G.Hymowitz, H.W.Christinger, G.Fuh, M.Ultsch, M.O'Connell, R.F.Kelley, A.Ashkenazi, A.M.de Vos.
 
  ABSTRACT  
 
Formation of a complex between Apo2L (also called TRAIL) and its signaling receptors, DR4 and DR5, triggers apoptosis by inducing the oligomerization of intracellular death domains. We report the crystal structure of the complex between Apo2L and the ectodomain of DR5. The structure shows three elongated receptors snuggled into long crevices between pairs of monomers of the homotrimeric ligand. The interface is divided into two distinct patches, one near the bottom of the complex close to the receptor cell surface and one near the top. Both patches contain residues that are critical for high-affinity binding. A comparison to the structure of the lymphotoxin-receptor complex suggests general principles of binding and specificity for ligand recognition in the TNF receptor superfamily.
 
  Selected figure(s)  
 
Figure 3.
Figure 3. Open Book View of the Apo2L–DR5 InterfaceApo2L and one receptor are rendered as space-filling models, while the other two receptors are shown as green tubes. Residues in the interface are colored by percent of buried accessible surface area upon complex formation (1%–25%, light yellow; 25%–50%, yellow; 50%–75%, orange; 75%–100%, red). The interface divides into two patches, A and B (labeled). A probe size of 1.4 Å was used to calculate accessible surface area.
Figure 6.
Figure 6. Superposition of DR5 with TNFR1TNFR1 (in lavender and gray) is taken from the lymphotoxin complex ([3]) and superimposed on DR5 (in red and black) based on the shared Cα atoms of CRD2. The sulfur atoms of the disulfide bonds in DR5 and TNFR1 are shown as yellow and orange spheres, respectively, and the 90s and 50s loops are highlighted in gray and black. The three CRDs are labeled. CRD2 and CRD3 mediate all contacts to the ligand.
 
  The above figures are reprinted by permission from Cell Press: Mol Cell (1999, 4, 563-571) copyright 1999.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
22543469 D.L.Lacey, W.J.Boyle, W.S.Simonet, P.J.Kostenuik, W.C.Dougall, J.K.Sullivan, J.San Martin, and R.Dansey (2012).
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
  Nat Rev Drug Discov, 11, 401-419.  
20422457 E.B.Lee, H.S.Jeon, S.S.Yoo, Y.Y.Choi, H.G.Kang, S.Cho, S.I.Cha, J.E.Choi, T.I.Park, B.H.Lee, R.W.Park, I.S.Kim, Y.M.Kang, C.H.Kim, S.Jheon, T.H.Jung, and J.Y.Park (2010).
Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer.
  Ann Surg Oncol, 17, 2608-2618.  
20531300 F.Gonzalvez, and A.Ashkenazi (2010).
New insights into apoptosis signaling by Apo2L/TRAIL.
  Oncogene, 29, 4752-4765.  
21059944 H.M.Ta, G.T.Nguyen, H.M.Jin, J.Choi, H.Park, N.Kim, H.Y.Hwang, and K.K.Kim (2010).
Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis.
  Proc Natl Acad Sci U S A, 107, 20281-20286.
PDB code: 3qbq
20156289 J.Vrielink, M.S.Heins, R.Setroikromo, E.Szegezdi, M.M.Mullally, A.Samali, and W.J.Quax (2010).
Synthetic constrained peptide selectively binds and antagonizes death receptor 5.
  FEBS J, 277, 1653-1665.  
20817427 P.D.Mace, and S.J.Riedl (2010).
Molecular cell death platforms and assemblies.
  Curr Opin Cell Biol, 22, 828-836.  
20406839 S.Wang, W.Ren, J.Liu, G.Lahat, K.Torres, G.Lopez, A.J.Lazar, A.Hayes-Jordan, K.Liu, J.Bankson, J.D.Hazle, and D.Lev (2010).
TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.
  Clin Cancer Res, 16, 2591-2604.  
  20068388 C.L.Dobson, S.Main, P.Newton, M.Chodorge, K.Cadwallader, R.Humphreys, V.Albert, T.J.Vaughan, R.R.Minter, and B.M.Edwards (2009).
Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.
  MAbs, 1, 552-562.  
19522538 C.Zhan, Q.Yan, Y.Patskovsky, Z.Li, R.Toro, A.Meyer, H.Cheng, M.Brenowitz, S.G.Nathenson, and S.C.Almo (2009).
Biochemical and structural characterization of the human TL1A ectodomain.
  Biochemistry, 48, 7636-7645.
PDB codes: 2qe3 2rjk 2rjl
18243765 F.Manzo, A.Nebbioso, M.Miceli, M.Conte, F.De Bellis, V.Carafa, G.Franci, F.P.Tambaro, and L.Altucci (2009).
TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.
  Int J Biochem Cell Biol, 41, 460-466.  
19229339 M.Jeong, Y.S.Kwon, S.H.Park, C.Y.Kim, S.S.Jeun, K.W.Song, Y.Ko, P.D.Robbins, T.R.Billiar, B.M.Kim, and D.W.Seol (2009).
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
  PLoS ONE, 4, e4545.  
  19147815 M.Razmara, B.Hilliard, A.K.Ziarani, R.Murali, S.Yellayi, M.Ghazanfar, Y.H.Chen, and M.L.Tykocinski (2009).
Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.
  Am J Pathol, 174, 460-474.  
19836385 P.A.Holoch, and T.S.Griffith (2009).
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.
  Eur J Pharmacol, 625, 63-72.  
18989337 A.Ashkenazi (2008).
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
  Nat Rev Drug Discov, 7, 1001-1012.  
18219321 C.Adams, K.Totpal, D.Lawrence, S.Marsters, R.Pitti, S.Yee, S.Ross, L.Deforge, H.Koeppen, M.Sagolla, D.Compaan, H.Lowman, S.Hymowitz, and A.Ashkenazi (2008).
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
  Cell Death Differ, 15, 751-761.
PDB code: 4od2
18613837 C.F.Ware (2008).
Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways.
  Immunol Rev, 223, 186-201.  
18094190 M.Reinisová, F.Senigl, X.Yin, J.Plachy, J.Geryk, D.Elleder, J.Svoboda, M.J.Federspiel, and J.Hejnar (2008).
A single-amino-acid substitution in the TvbS1 receptor results in decreased susceptibility to infection by avian sarcoma and leukosis virus subgroups B and D and resistance to infection by subgroup E in vitro and in vivo.
  J Virol, 82, 2097-2105.  
18328427 S.Kleber, I.Sancho-Martinez, B.Wiestler, A.Beisel, C.Gieffers, O.Hill, M.Thiemann, W.Mueller, J.Sykora, A.Kuhn, N.Schreglmann, E.Letellier, C.Zuliani, S.Klussmann, M.Teodorczyk, H.J.Gröne, T.M.Ganten, H.Sültmann, J.Tüttenberg, A.von Deimling, A.Regnier-Vigouroux, C.Herold-Mende, and A.Martin-Villalba (2008).
Yes and PI3K bind CD95 to signal invasion of glioblastoma.
  Cancer Cell, 13, 235-248.  
17671978 T.A.Wassenaar, W.J.Quax, and A.E.Mark (2008).
The conformation of the extracellular binding domain of Death Receptor 5 in the presence and absence of the activating ligand TRAIL: a molecular dynamics study.
  Proteins, 70, 333-343.  
18096641 V.Pulim, J.Bienkowska, and B.Berger (2008).
LTHREADER: Prediction of extracellular ligand-receptor interactions in cytokines using localized threading.
  Protein Sci, 17, 279-292.  
17724141 D.Daniel, B.Yang, D.A.Lawrence, K.Totpal, I.Balter, W.P.Lee, A.Gogineni, M.J.Cole, S.F.Yee, S.Ross, and A.Ashkenazi (2007).
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
  Blood, 110, 4037-4046.  
17449269 F.K.Chan (2007).
Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling.
  Cytokine, 37, 101-107.  
17656251 H.Ye, N.Pungpravat, B.L.Huang, L.L.Muzio, M.A.Mariggiò, Z.Chen, D.T.Wong, and X.Zhou (2007).
Genomic assessments of the frequent loss of heterozygosity region on 8p21.3-p22 in head and neck squamous cell carcinoma.
  Cancer Genet Cytogenet, 176, 100-106.  
17767167 K.W.Wagner, E.A.Punnoose, T.Januario, D.A.Lawrence, R.M.Pitti, K.Lancaster, D.Lee, M.von Goetz, S.F.Yee, K.Totpal, L.Huw, V.Katta, G.Cavet, S.G.Hymowitz, L.Amler, and A.Ashkenazi (2007).
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL.
  Nat Med, 13, 1070-1077.  
17666396 L.Bin, J.Thorburn, L.R.Thomas, P.E.Clark, R.Humphreys, and A.Thorburn (2007).
Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding.
  J Biol Chem, 282, 28189-28194.  
17917057 M.P.Simons, W.M.Nauseef, and T.S.Griffith (2007).
Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.
  Immunol Res, 39, 79-93.  
17492935 W.D.Tap, N.Federman, and F.C.Eilber (2007).
Targeted therapies for soft-tissue sarcomas.
  Expert Rev Anticancer Ther, 7, 725-733.  
17318333 Y.S.Youn, M.J.Shin, S.Y.Chae, C.H.Jin, T.H.Kim, and K.C.Lee (2007).
Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
  Biotechnol Lett, 29, 713-721.  
16807107 A.Kinkade, and C.F.Ware (2006).
The DARC conspiracy--virus invasion tactics.
  Trends Immunol, 27, 362-367.  
16731632 A.M.van der Sloot, V.Tur, E.Szegezdi, M.M.Mullally, R.H.Cool, A.Samali, L.Serrano, and W.J.Quax (2006).
Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
  Proc Natl Acad Sci U S A, 103, 8634-8639.  
16799759 A.Y.Sun, Y.L.Shen, J.C.Yin, H.Zhang, Y.N.Tang, and D.Z.Wei (2006).
Improvement of expression level and bioactivity of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) by a novel zinc ion feeding strategy.
  Biotechnol Lett, 28, 1215-1219.  
16840353 B.J.Willett, E.L.McMonagle, F.Bonci, M.Pistello, and M.J.Hosie (2006).
Mapping the domains of CD134 as a functional receptor for feline immunodeficiency virus.
  J Virol, 80, 7744-7747.  
16547002 C.Bossen, K.Ingold, A.Tardivel, J.L.Bodmer, O.Gaide, S.Hertig, C.Ambrose, J.Tschopp, and P.Schneider (2006).
Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human.
  J Biol Chem, 281, 13964-13971.  
16710361 C.Sandu, G.Morisawa, I.Wegorzewska, T.Huang, A.F.Arechiga, J.M.Hill, T.Kim, C.M.Walsh, and M.H.Werner (2006).
FADD self-association is required for stable interaction with an activated death receptor.
  Cell Death Differ, 13, 2052-2061.  
16195699 C.Y.Kim, M.Jeong, H.Mushiake, B.M.Kim, W.B.Kim, J.P.Ko, M.H.Kim, M.Kim, T.H.Kim, P.D.Robbins, T.R.Billiar, and D.W.Seol (2006).
Cancer gene therapy using a novel secretable trimeric TRAIL.
  Gene Ther, 13, 330-338.  
16905106 D.M.Compaan, and S.G.Hymowitz (2006).
The crystal structure of the costimulatory OX40-OX40L complex.
  Structure, 14, 1321-1330.
PDB codes: 2hev 2hew 2hey
16680194 K.Aoki, H.Saito, C.Itzstein, M.Ishiguro, T.Shibata, R.Blanque, A.H.Mian, M.Takahashi, Y.Suzuki, M.Yoshimatsu, A.Yamaguchi, P.Deprez, P.Mollat, R.Murali, K.Ohya, W.C.Horne, and R.Baron (2006).
A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.
  J Clin Invest, 116, 1525-1534.  
16187084 K.Tamada, and L.Chen (2006).
Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules.
  Cancer Immunol Immunother, 55, 355-362.  
16217763 S.Wolf, D.Mertens, A.Pscherer, P.Schroeter, D.Winkler, H.J.Gröne, C.Hofele, K.Hemminki, R.Kumar, G.Steineck, H.Döhner, S.Stilgenbauer, and P.Lichter (2006).
Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer.
  Int J Cancer, 118, 1831-1835.  
16772303 T.Murata, M.Tsuboi, K.Hikita, and N.Kaneda (2006).
Protective effects of neurotrophic factors on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of murine adrenal chromaffin cell line tsAM5D.
  J Biol Chem, 281, 22503-22516.  
16767747 Y.Jiang, K.Chen, Z.Tang, Z.Zeng, W.Yao, D.Sun, W.Ka, D.He, Z.Wen, and S.Chien (2006).
TRAIL gene reorganizes the cytoskeleton and decreases the motility of human leukemic Jurkat cells.
  Cell Motil Cytoskeleton, 63, 471-482.  
16169851 D.M.Compaan, L.C.Gonzalez, I.Tom, K.M.Loyet, D.Eaton, and S.G.Hymowitz (2005).
Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex.
  J Biol Chem, 280, 39553-39561.
PDB code: 2aw2
16361820 K.U.Kim, S.Y.Seo, K.Y.Heo, Y.H.Yoo, H.J.Kim, H.S.Lee, S.S.Choi, T.H.Hwang, and H.J.Lee (2005).
Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells.
  J Korean Med Sci, 20, 1046-1052.  
16319225 L.Clancy, K.Mruk, K.Archer, M.Woelfel, J.Mongkolsapaya, G.Screaton, M.J.Lenardo, and F.K.Chan (2005).
Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis.
  Proc Natl Acad Sci U S A, 102, 18099-18104.  
15672328 M.Mita, and A.W.Tolcher (2005).
Novel apoptosis inducing agents in cancer therapy.
  Curr Probl Cancer, 29, 8.  
16212486 N.Yan, and Y.Shi (2005).
Mechanisms of apoptosis through structural biology.
  Annu Rev Cell Dev Biol, 21, 35-56.  
15520016 R.F.Kelley, K.Totpal, S.H.Lindstrom, M.Mathieu, K.Billeci, L.Deforge, R.Pai, S.G.Hymowitz, and A.Ashkenazi (2005).
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.
  J Biol Chem, 280, 2205-2212.  
15711921 S.Bouralexis, D.M.Findlay, and A.Evdokiou (2005).
Death to the bad guys: targeting cancer via Apo2L/TRAIL.
  Apoptosis, 10, 35-51.  
15542592 S.G.Hymowitz, D.R.Patel, H.J.Wallweber, S.Runyon, M.Yan, J.Yin, S.K.Shriver, N.C.Gordon, B.Pan, N.J.Skelton, R.F.Kelley, and M.A.Starovasnik (2005).
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding.
  J Biol Chem, 280, 7218-7227.
PDB codes: 1xu1 1xu2 1xut
16239906 S.W.Fesik (2005).
Promoting apoptosis as a strategy for cancer drug discovery.
  Nat Rev Cancer, 5, 876-885.  
16234248 Y.Guo, C.Chen, Y.Zheng, J.Zhang, X.Tao, S.Liu, D.Zheng, and Y.Liu (2005).
A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death.
  J Biol Chem, 280, 41940-41952.  
  16260391 Y.Huang, N.Erdmann, J.Zhao, and J.Zheng (2005).
The signaling and apoptotic effects of TNF-related apoptosis-inducing ligand in HIV-1 associated dementia.
  Neurotox Res, 8, 135-148.  
15093829 G.Zhang (2004).
Tumor necrosis factor family ligand-receptor binding.
  Curr Opin Struct Biol, 14, 154-160.  
14980075 M.W.Taylor, W.M.Grosse, J.E.Schaley, C.Sanda, X.Wu, S.C.Chien, F.Smith, T.G.Wu, M.Stephens, M.W.Ferris, J.N.McClintick, R.E.Jerome, and H.J.Edenberg (2004).
Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro.
  J Interferon Cytokine Res, 24, 107-118.  
15389537 R.Di Pietro, and G.Zauli (2004).
Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.
  J Cell Physiol, 201, 331-340.  
15158769 S.Shankar, and R.K.Srivastava (2004).
Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications.
  Drug Resist Updat, 7, 139-156.  
15511228 S.Y.Park, J.W.Seol, Y.J.Lee, J.H.Cho, H.S.Kang, I.S.Kim, S.H.Park, T.H.Kim, J.H.Yim, M.Kim, T.R.Billiar, and D.W.Seol (2004).
IFN-gamma enhances TRAIL-induced apoptosis through IRF-1.
  Eur J Biochem, 271, 4222-4228.  
15562003 T.Mori, A.Oguro, T.Ohtsu, and Y.Nakamura (2004).
RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family.
  Nucleic Acids Res, 32, 6120-6128.  
15095280 W.F.Holmes, D.R.Soprano, and K.J.Soprano (2004).
Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines.
  J Cell Physiol, 199, 317-329.  
12787570 A.Almasan, and A.Ashkenazi (2003).
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.
  Cytokine Growth Factor Rev, 14, 337-348.  
12427767 F.Mackay, P.Schneider, P.Rennert, and J.Browning (2003).
BAFF AND APRIL: a tutorial on B cell survival.
  Annu Rev Immunol, 21, 231-264.  
12715002 H.M.Kim, K.S.Yu, M.E.Lee, D.R.Shin, Y.S.Kim, S.G.Paik, O.J.Yoo, H.Lee, and J.O.Lee (2003).
Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation.
  Nat Struct Biol, 10, 342-348.
PDB codes: 1otz 1p0t
12485619 H.Wajant, K.Pfizenmaier, and P.Scheurich (2003).
Non-apoptotic Fas signaling.
  Cytokine Growth Factor Rev, 14, 53-66.  
12466268 P.Schneider, D.Olson, A.Tardivel, B.Browning, A.Lugovskoy, D.Gong, M.Dobles, S.Hertig, K.Hofmann, H.Van Vlijmen, Y.M.Hsu, L.C.Burkly, J.Tschopp, and T.S.Zheng (2003).
Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
  J Biol Chem, 278, 5444-5454.  
14656435 S.G.Hymowitz, D.M.Compaan, M.Yan, H.J.Wallweber, V.M.Dixit, M.A.Starovasnik, and A.M.de Vos (2003).
The crystal structures of EDA-A1 and EDA-A2: splice variants with distinct receptor specificity.
  Structure, 11, 1513-1520.
PDB codes: 1rj7 1rj8
12721620 Y.Liu, X.Hong, J.Kappler, L.Jiang, R.Zhang, L.Xu, C.H.Pan, W.E.Martin, R.C.Murphy, H.B.Shu, S.Dai, and G.Zhang (2003).
Ligand-receptor binding revealed by the TNF family member TALL-1.
  Nature, 423, 49-56.
PDB codes: 1oqd 1oqe
12189384 A.Ashkenazi (2002).
Targeting death and decoy receptors of the tumour-necrosis factor superfamily.
  Nat Rev Cancer, 2, 420-430.  
11862220 D.A.Oren, Y.Li, Y.Volovik, T.S.Morris, C.Dharia, K.Das, O.Galperina, R.Gentz, and E.Arnold (2002).
Structural basis of BLyS receptor recognition.
  Nat Struct Biol, 9, 288-292.
PDB code: 1kxg
11991969 D.J.Knauss, and J.A.Young (2002).
A fifteen-amino-acid TVB peptide serves as a minimal soluble receptor for subgroup B avian leukosis and sarcoma viruses.
  J Virol, 76, 5404-5410.  
12392561 G.H.Nam, and K.Y.Choi (2002).
Association of human tumor necrosis factor-related apoptosis inducing ligand with membrane upon acidification.
  Eur J Biochem, 269, 5280-5287.  
11796220 J.L.Bodmer, P.Schneider, and J.Tschopp (2002).
The molecular architecture of the TNF superfamily.
  Trends Biochem Sci, 27, 19-26.  
12414956 K.Kabsch, and A.Alonso (2002).
The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms.
  J Virol, 76, 12162-12172.  
11733492 S.Ito, K.Wakabayashi, O.Ubukata, S.Hayashi, F.Okada, and T.Hata (2002).
Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution.
  J Biol Chem, 277, 6631-6636.
PDB code: 1iqa
11562359 B.G.Werneburg, S.J.Zoog, T.T.Dang, M.R.Kehry, and J.J.Crute (2001).
Molecular characterization of CD40 signaling intermediates.
  J Biol Chem, 276, 43334-43342.  
11264341 H.B.Adkins, S.C.Blacklow, and J.A.Young (2001).
Two functionally distinct forms of a retroviral receptor explain the nonreciprocal receptor interference among subgroups B, D, and E avian leukosis viruses.
  J Virol, 75, 3520-3526.  
11507096 H.Higuchi, S.F.Bronk, Y.Takikawa, N.Werneburg, R.Takimoto, W.El-Deiry, and G.J.Gores (2001).
The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis.
  J Biol Chem, 276, 38610-38618.  
11991679 J.Held, and K.Schulze-Osthoff (2001).
Potential and caveats of TRAIL in cancer therapy.
  Drug Resist Updat, 4, 243-252.  
  11581298 J.Lam, C.A.Nelson, F.P.Ross, S.L.Teitelbaum, and D.H.Fremont (2001).
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity.
  J Clin Invest, 108, 971-979.
PDB code: 1jtz
11525169 M.Karpusas, J.Lucci, J.Ferrant, C.Benjamin, F.R.Taylor, K.Strauch, E.Garber, and Y.M.Hsu (2001).
Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody.
  Structure, 9, 321-329.
PDB code: 1i9r
11239407 R.M.Locksley, N.Killeen, and M.J.Lenardo (2001).
The TNF and TNF receptor superfamilies: integrating mammalian biology.
  Cell, 104, 487-501.  
11574464 S.G.Hymowitz, E.H.Filvaroff, J.P.Yin, J.Lee, L.Cai, P.Risser, M.Maruoka, W.Mao, J.Foster, R.F.Kelley, G.Pan, A.L.Gurney, A.M.de Vos, and M.A.Starovasnik (2001).
IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding.
  EMBO J, 20, 5332-5341.
PDB code: 1jpy
11828422 U.Sartorius, I.Schmitz, and P.H.Krammer (2001).
Molecular mechanisms of death-receptor-mediated apoptosis.
  Chembiochem, 2, 20-29.  
11114500 E.Y.Jones (2000).
The tumour necrosis factor receptor family: life or death choices.
  Curr Opin Struct Biol, 10, 644-648.  
10894161 F.C.Kischkel, D.A.Lawrence, A.Chuntharapai, P.Schow, K.J.Kim, and A.Ashkenazi (2000).
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.
  Immunity, 12, 611-620.  
11053089 F.K.Chan (2000).
The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function.
  Ann Rheum Dis, 59, i50-i53.  
11015187 F.P.Ottensmeyer, D.R.Beniac, R.Z.Luo, and C.C.Yip (2000).
Mechanism of transmembrane signaling: insulin binding and the insulin receptor.
  Biochemistry, 39, 12103-12112.  
10781406 G.Screaton, and X.N.Xu (2000).
T cell life and death signalling via TNF-receptor family members.
  Curr Opin Immunol, 12, 316-322.  
10891884 H.T.Idriss, and J.H.Naismith (2000).
TNF alpha and the TNF receptor superfamily: structure-function relationship(s).
  Microsc Res Tech, 50, 184-195.  
10880534 J.S.Thompson, P.Schneider, S.L.Kalled, L.Wang, E.A.Lefevre, T.G.Cachero, F.MacKay, S.A.Bixler, M.Zafari, Z.Y.Liu, S.A.Woodcock, F.Qian, M.Batten, C.Madry, Y.Richard, C.D.Benjamin, J.L.Browning, A.Tsapis, J.Tschopp, and C.Ambrose (2000).
BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population.
  J Exp Med, 192, 129-135.  
10753817 M.C.Deller, and E.Yvonne Jones (2000).
Cell surface receptors.
  Curr Opin Struct Biol, 10, 213-219.  
10651627 S.G.Hymowitz, M.P.O'Connell, M.H.Ultsch, A.Hurst, K.Totpal, A.Ashkenazi, A.M.de Vos, and R.F.Kelley (2000).
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL.
  Biochemistry, 39, 633-640.
PDB code: 1dg6
11057900 S.W.Fesik (2000).
Insights into programmed cell death through structural biology.
  Cell, 103, 273-282.  
10958661 Y.Lin, A.Devin, A.Cook, M.M.Keane, M.Kelliher, S.Lipkowitz, and Z.G.Liu (2000).
The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase.
  Mol Cell Biol, 20, 6638-6645.  
11232332 S.M.McWhirter, S.S.Pullen, B.G.Werneburg, M.E.Labadia, R.H.Ingraham, J.J.Crute, M.R.Kehry, and T.Alber (1999).
Structural and biochemical analysis of signal transduction by the TRAF family of adapter proteins.
  Cold Spring Harb Symp Quant Biol, 64, 551-562.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.

 

spacer

spacer